Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers

著录项

• 来源
  《European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)》 |2016年第null期|共1页
• 作者

  Yap T. A.; Krebs M. G.; Postel-Vinay S.; Bang Y. J.; El-Khoueiry A.; Abida W.; Harrington K.; Sundar R.; Carter L.; Castanon-Alvarez E.; Im S. A.; Berges A.; Khan M.; Stephens C.; Ross G.; Soria J. C.;

  展开▼
• 作者单位

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类 肿瘤学;
• 关键词